20-HETE receptor (GPR75) antagonists and methods of use

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11690825
SERIAL NO

16083404

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NEW YORK MEDICAL COLLEGEADMINISTRATION BUILDING VALHALLA NY 10595

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Falck, John R Austin, US 39 251
Garcia, Victor Valhalla, US 44 233
Schwartzman, Michal L Valhalla, US 8 65

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 4, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 4, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00